The American Journal of Medicine

Slides:

Advertisements

Similar presentations

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Practical Management of Anticoagulation in Patients.

Advertisements

High Positive End-Expiratory Pressure Is Associated with Improved Survival in Obese Patients with Acute Respiratory Distress Syndrome Christian Bime,

Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study Lars Frost, MD, PhD, Lone Juul Hune,

Volume 149, Issue 6, Pages (June 2016)

Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated.

Heart, Lung and Circulation

Quadriceps Strength as a Predictor of Mortality in Coronary Artery Disease Kentaro Kamiya, PT, PhD, Takashi Masuda, MD, PhD, Shinya Tanaka, PT, MSc, Nobuaki.

Influence of Body Mass Index on Long-Term Survival After Cardiac Catheterization Barak Zafrir, MD, Ronen Jaffe, MD, Ronen Rubinshtein, MD, Basheer Karkabi,

Personalized Activity Intelligence (PAI) for Prevention of Cardiovascular Disease and Promotion of Physical Activity Bjarne M. Nes, PhD, Christian R.

Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal Gregory.

Hazard ratio (HR) for mortality for a 1-kg/m2 increase in body mass index (BMI) across the range of baseline BMI among patients with acute ischemic stroke.

Volume 14, Issue 6, Pages (June 2017)

Role of the CHADS2 Score in Acute Coronary Syndromes

Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B

2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Laurent Macle, MD, John Cairns, MD, Kori.

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD,

Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

David D. McManus, MD, ScM, Wei Huang, MS, Kunal V

Nat. Rev. Cardiol. doi: /nrcardio

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD,

Volume 15, Issue 1, Pages (January 2018)

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Selecting NOACs for High-Risk Patients

Introduction The American Journal of Medicine

Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study Lars Frost, MD, PhD, Lone Juul Hune,

CHA2DS2-VASc Score Is Directly Associated with the Risk of Pulmonary Embolism in Patients with Atrial Fibrillation Walid Saliba, MD, MPH, Gad Rennert,

Eric L. Eisenstein, DBA, Darren K. McGuire, MD, MHS, Manjushri V

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials Giulia Renda, MD, PhD, Marta.

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation Giulia Renda, MD, PhD, Marco.

SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation Pilar Gallego, MD, PhD, Vanessa Roldán,

Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease Nina Raju, MD, MsC, Magdalena Sobieraj-Teague, MBBS, Jack Hirsh, MD,

Epidemiology of Myelodysplastic Syndromes

Volume 14, Issue 6, Pages (June 2017)

David D. McManus, MD, ScM, Wei Huang, MS, Kunal V

Gregory Y.H. Lip, MD, Jonathan L. Halperin, MD, Hung-Fat Tse, MD, PhD

Low-dose Aspirin and Cancer Mortality: A Meta-analysis of Randomized Trials Edward J. Mills, PhD, MSc, Ping Wu, MD, MSc, Mark Alberton, BSc, Steve Kanters,

Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease Renato D. Lopes, MD, MHS, PhD, Meena Rao, MD,

CHADS2 Score, Statin Therapy, and Risks of Atrial Fibrillation

Jessica L. Lee, MD, MS, Esther S. Oh, MD, Rebecca W. Lee, MD, Thomas E

TIA for the Internist The American Journal of Medicine

Hong-Tao Tie, MD, Rui Shi, MD The American Journal of Medicine

History of Thyroid Disorders in Relation to Clinical Outcomes in Atrial Fibrillation Helene Bruere, MD, Laurent Fauchier, MD, PhD, Anne Bernard Brunet,

The Obesity Paradox, Weight Loss, and Coronary Disease

Personalized Activity Intelligence (PAI) for Prevention of Cardiovascular Disease and Promotion of Physical Activity Bjarne M. Nes, PhD, Christian R.

Truman J. Milling, MD, Alex C. Spyropoulos, MD

Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin Keitaro Senoo, MD, Marco Proietti,

Interaction of Physical Activity and Body Mass Index on Mortality in Coronary Heart Disease: Data from the Nord-Trøndelag Health Study Trine Moholdt,

2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Atul Verma, MD, John A. Cairns, MD, L.

Isla M. Ogilvie, PhD, Nick Newton, PhD, Sharon A

Quadriceps Strength as a Predictor of Mortality in Coronary Artery Disease Kentaro Kamiya, PT, PhD, Takashi Masuda, MD, PhD, Shinya Tanaka, PT, MSc, Nobuaki.

Molly E. Waring, PhD, Jane S

Off-pump versus on-pump coronary artery bypass grafting: Insights from the Arterial Revascularization Trial Umberto Benedetto, MD, PhD, Douglas G. Altman,

2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Jason G. Andrade, MD, Atul Verma, MD,

Recent Temporal Changes in Atherosclerotic Cardiovascular Diseases in Ontario: Clinical and Health Systems Impact Jack V. Tu, MD, PhD, Anam M. Khan,

Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter

Ultra-Sensitive Copeptin and Cardiac Troponin in Diagnosing Non-ST-Segment Elevation Acute Coronary Syndromes—The COPACS Study Fabrizio Ricci, MD, Rosa.

Stroke and Bleeding Risk Co-distribution in Real-world Patients with Atrial Fibrillation: The Euro Heart Survey Maura Marcucci, MD, Gregory Y.H. Lip,

Long-term Effect of Chronic Oral Anticoagulation with Warfarin after Acute Myocardial Infarction Salman A. Haq, MD, John F. Heitner, MD, Terrence J.

National Trends in Ambulatory Oral Anticoagulant Use

Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation

The American Journal of Medicine

Erratum Canadian Journal of Cardiology

Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation Giulia Renda, MD, PhD, Marco.

Forest plot illustrating the risk ratio of any bleeding and GRADE assessment. AF, atrial fibrillation; DOAC, advent of direct oral anticoagulants; PCI,

Figure 8. Stroke prevention strategy in patients with AF

Figure 1. Decision-making process of stroke prevention in patients with AF from Asia. The decision-making process includes stroke risk evaluation, OAC.

Forest plot illustrating the risk ratio of major bleeding

Volume 14, Issue 6, Pages (June 2017)

Presentation transcript:

The American Journal of Medicine Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation Giuseppe Patti, MD, Ladislav Pecen, PhD, Markus Lucerna, PhD, Kurt Huber, MD, Miklos Rohla, MD, PhD, Giulia Renda, MD, PhD, Jolanta Siller-Matula, MD, Fabrizio Ricci, MD, Paulus Kirchhof, MD, Raffaele De Caterina, MD, PhD The American Journal of Medicine DOI: 10.1016/j.amjmed.2018.12.036 Copyright © 2019 The Authors Terms and Conditions

Figure 1 Incidence and related adjusted odds ratios (OR) for the net composite endpoint* and its individual components in patients receiving NOACs or VKAs. CV = cardiovascular; NOACs = non-vitamin K antagonist oral anticoagulants; VKAs = vitamin K antagonists. *The net composite endpoint included major bleeding and ischemic cardiovascular events (cardiac events [acute coronary syndrome, coronary revascularization] + vascular events [stroke, transient ischemic attack, systemic embolic events]). The American Journal of Medicine DOI: (10.1016/j.amjmed.2018.12.036) Copyright © 2019 The Authors Terms and Conditions

Figure 2 Analysis on the net composite endpoint with different NOACs vs VKAs. NOACs = non-vitamin K antagonist oral anticoagulants; OR = odds ratio; SEE = systemic embolic events; TIA = transient ischemic attack; VKAs = vitamin K antagonists. The American Journal of Medicine DOI: (10.1016/j.amjmed.2018.12.036) Copyright © 2019 The Authors Terms and Conditions

Figure 3 Odds ratios (OR) for major bleeding with NOACs vs VKAs in elderly patients (aged ≥75 years), elderly patients with BMI <24.7 kg/m2, and very elderly patients (aged ≥85 years). BMI = body mass index; NOACs = non-vitamin K antagonist oral anticoagulants; VKAs = vitamin K antagonists. The American Journal of Medicine DOI: (10.1016/j.amjmed.2018.12.036) Copyright © 2019 The Authors Terms and Conditions

Supplementary Figure Flow diagram showing how the final study population was derived from the 2 registries. NOACs = non-vitamin K antagonist oral anticoagulants; OAC = oral anticoagulant therapy; VKAs = vitamin K antagonists. The American Journal of Medicine DOI: (10.1016/j.amjmed.2018.12.036) Copyright © 2019 The Authors Terms and Conditions